Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Calyx and Qynapse Partnering to Enable AI-enhanced Medical Imaging Services for CNS Clinical Trials

Partnership delivers advanced approaches for bringing neurodegenerative disease treatments to market .

Calyx, the eClinical and Regulatory solutions and services provider relied on for solving complex data challenges in clinical research,announced it has entered into a partnership with Qynapse, an Artificial Intelligence (AI) neuroimaging medical technology company. The partnership enables Calyx to adopt and deliver Qynapse’s precise and objective AI-powered neuroimaging analysis solutions, QyScore and QyPredict to its global pharmaceutical and biotech customers as they develop new medical treatments for central nervous system (CNS) disorders.

Recommended AI News: WideOrbit Introduces Automated Addressable Ad Replacement for Live-Streamed Broadcast TV Content

“We’re delighted to add Qynapse’s advanced analysis capabilities to our full suite of proven medical imaging services,” said Stephen M. Bravo, MD, Chief Medical Officer at Calyx. “This groundbreaking services and technology partnership will enable our clients to more confidently assess the full potential of treatments in development for Multiple Sclerosis, Parkinson’s, Alzheimer’s, and Huntington’s disease, as well as other neurodegenerative disorders.”

Related Posts
1 of 30,448

Recommended AI News: WideOrbit Introduces Automated Addressable Ad Replacement for Live-Streamed Broadcast TV Content

Qynapse has developed one of the largest datasets of proprietary algorithms designed to rapidly analyze and interpret brain scans, delivering more objectivity and precision for the measurement of drug efficacy and safety during CNS clinical trials. Calyx’s Medical Imaging services have been proven in over 2,600 global clinical trials, delivering reliable data that has supported the approval of over 270 new medical treatments.

“We are excited to partner with Calyx, a Medical Imaging and eClinical solutions powerhouse, in bringing life-changing treatments to patients globally,” said Olivier Courrèges, Chief Executive Officer at Qynapse. “Working together we will further expedite and improve the go-to-market process for CNS drug therapies.”

Recommended AI News: Avera Health and Sema4 Announce Data-driven Study to Advance Cancer Treatment Across the Avera Service Area

[To share your insights with us, please write to sghosh@martechseries.com]

Comments are closed.